# A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

> **NCT06085664** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 42 (estimated)

## Conditions studied

- Prostate Cancer
- Radical Prostatectomy

## Interventions

- **DRUG:** REGN5678
- **DRUG:** Piflufolastat F18

## Key facts

- **NCT ID:** NCT06085664
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085664, "A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06085664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*